Table of Contents
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Substance (Drug) Abuse to Central Nervous System Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Substance (Drug) Abuse to Central Nervous System Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Substance (Drug) Abuse Therapeutics Clinical Trials 30
Prominent Drugs 31
Clinical Trial Profile Snapshots 32
Appendix 654
Abbreviations 654
Definitions 654
Research Methodology 655
Secondary Research 655
About GlobalData 656
Contact Us 656
Source 657
Substance (Drug) Abuse Therapeutics, Global, Clinical Trials by Region, 2019* 7
Substance (Drug) Abuse Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
Substance (Drug) Abuse Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 10
Substance (Drug) Abuse Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 11
Substance (Drug) Abuse Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 12
Substance (Drug) Abuse Therapeutics Clinical Trials, North America, Top Countries, 2019* 13
Substance (Drug) Abuse Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2019* 14
Substance (Drug) Abuse Therapeutics Clinical Trials, Central and South America, Top Countries, 2019* 15
Proportion of Substance (Drug) Abuse to Central Nervous System Clinical Trials, G7 Countries (%), 2019* 16
Substance (Drug) Abuse Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 17
Substance (Drug) Abuse Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 18
Proportion of Substance (Drug) Abuse to Central Nervous System Clinical Trials, E7 Countries (%), 2019* 19
Substance (Drug) Abuse Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 20
Substance (Drug) Abuse Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 21
Substance (Drug) Abuse Therapeutics, Global, Clinical Trials by Phase, 2019* 22
Substance (Drug) Abuse Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 23
Substance (Drug) Abuse Therapeutics, Global, Clinical Trials by Trial Status, 2019* 24
Substance (Drug) Abuse Therapeutics Clinical Trials, Global, by End Point Status, 2019* 25
Substance (Drug) Abuse Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 26
Substance (Drug) Abuse Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 27
Substance (Drug) Abuse Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 29
Substance (Drug) Abuse Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 30
Substance (Drug) Abuse Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 31
List of Figures
Substance (Drug) Abuse Therapeutics, Global, Clinical Trials by Region (%), 2019* 7
Substance (Drug) Abuse Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 8
Substance (Drug) Abuse Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 10
Substance (Drug) Abuse Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 11
Substance (Drug) Abuse Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 12
Substance (Drug) Abuse Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 13
Substance (Drug) Abuse Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2019* 14
Substance (Drug) Abuse Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2019* 15
Proportion of Substance (Drug) Abuse to Central Nervous System Clinical Trials, G7 Countries (%), 2019* 16
Substance (Drug) Abuse Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 17
Substance (Drug) Abuse Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 18
Proportion of Substance (Drug) Abuse to Central Nervous System Clinical Trials, E7 Countries (%), 2019* 19
Substance (Drug) Abuse Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 20
Substance (Drug) Abuse Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 21
Substance (Drug) Abuse Therapeutics, Global, Clinical Trials by Phase (%), 2019* 22
Substance (Drug) Abuse Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 23
Substance (Drug) Abuse Therapeutics, Global, Clinical Trials by Trial Status, 2019* 24
Substance (Drug) Abuse Therapeutics Clinical Trials, Global, by End Point Status, 2019* 25
Substance (Drug) Abuse Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 26
Substance (Drug) Abuse Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 27
Substance (Drug) Abuse Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 28
Substance (Drug) Abuse Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 30
Substance (Drug) Abuse Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 31
GlobalData Methodology 655
【免責事項】
https://www.marketreport.jp/reports-disclaimer